The Physiology, Signaling, and Pharmacology of Dopamine Receptors
暂无分享,去创建一个
[1] A. Carlsson,et al. 3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine Antagonists , 1957, Nature.
[2] O. Hornykiewicz,et al. [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system]. , 1998, Klinische Wochenschrift.
[3] O. Hornykiewicz,et al. [The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia]. , 1961, Wiener klinische Wochenschrift.
[4] K. Fuxe,et al. EVIDENCE FOR THE EXISTENCE OF MONOAMINE-CONTAINING NEURONS IN THE CENTRAL NERVOUS SYSTEM. I. DEMONSTRATION OF MONOAMINES IN THE CELL BODIES OF BRAIN STEM NEURONS. , 1964, Acta physiologica Scandinavica. Supplementum.
[5] K. Fuxe,et al. DEMONSTRATION AND MAPPING OUT OF NIGRO-NEOSTRIATAL DOPAMINE NEURONS. , 1964, Life sciences.
[6] S. Snyder,et al. The role of brain dopamine in behavioral regulation and the actions of psychotropic drugs. , 1970, The American journal of psychiatry.
[7] M. Tomkiewicz,et al. Lithium attenuates Drug-induced Hyperactivity in Rats , 1971, Nature.
[8] P. Greengard,et al. Dopamine-Sensitive Adenyl Cyclase: Possible Role in Synaptic Transmission , 1971, Science.
[9] S H Snyder,et al. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs , 1976, Science.
[10] P. Seeman,et al. Antipsychotic drug doses and neuroleptic/dopamine receptors , 1976, Nature.
[11] P. Spano,et al. Studies on the pharmacological properties of dopamine receptors in various areas of the central nervous system. , 1978, Advances in biochemical psychopharmacology.
[12] J. Kebabian,et al. Multiple receptors for dopamine , 1979, Nature.
[13] P. Cohen,et al. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. , 1980, European journal of biochemistry.
[14] P. Cohen,et al. Glycogen synthase kinase-3 from rabbit skeletal muscle. , 2005, Methods in enzymology.
[15] J. Bockaert,et al. Pharmacological characterization of the D2 dopamine receptor negatively coupled with adenylate cyclase in rat anterior pituitary. , 1983, Molecular pharmacology.
[16] P. Greengard,et al. DARPP-32, a dopamine- and adenosine 3':5'-monophosphate-regulated neuronal phosphoprotein. II. Comparison of the kinetics of phosphorylation of DARPP-32 and phosphatase inhibitor 1. , 1984, The Journal of biological chemistry.
[17] P. Greengard,et al. DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1 , 1984, Nature.
[18] A. Carlsson. Perspectives on the discovery of central monoaminergic neurotransmission. , 1987, Annual review of neuroscience.
[19] D. Choi. Ionic dependence of glutamate neurotoxicity , 1987, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[20] F. J. White,et al. Is stimulation of both D1 and D2 receptors necessary for the expression of dopamine-mediated behaviors? , 1988, Pharmacology Biochemistry and Behavior.
[21] D. Grandy,et al. Cloning and expression of a rat D2 dopamine receptor cDNA , 1988, Nature.
[22] C. Gerfen,et al. Multiple D2 dopamine receptors produced by alternative RNA splicing , 1989, Nature.
[23] J. Axelrod,et al. The dopamine-1 agonist, SKF 82526, stimulates phospholipase-C activity independent of adenylate cyclase. , 1989, The Journal of pharmacology and experimental therapeutics.
[24] M. Martres,et al. Alternative splicing directs the expression of two D2 dopamine receptor isoforms , 1989, Nature.
[25] P. Greengard,et al. Striatal phosphoproteins in Parkinson disease and progressive supranuclear palsy. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[26] P. Greengard,et al. Phosphorylation of DARPP-32, a dopamine- and cAMP-regulated phosphoprotein, by casein kinase II. , 1989, The Journal of biological chemistry.
[27] D. Grandy,et al. Cloning and expression of human and rat Dt dopamine receptors , 1990, Nature.
[28] D. Grandy,et al. Cloning and expression of human and rat D1 dopamine receptors. , 1990, Nature.
[29] Bruno Giros,et al. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics , 1990, Nature.
[30] M. Okuda,et al. [Dopamine receptor]. , 1990, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.
[31] M. Caron,et al. Molecular cloning and expression of the gene for a human D1 dopamine receptor , 1990, Nature.
[32] R. Roth,et al. Autoreceptor Regulation of Dopamine Synthesis , 1990, Annals of the New York Academy of Sciences.
[33] M. Caron,et al. beta-Arrestin: a protein that regulates beta-adrenergic receptor function. , 1990, Science.
[34] G. Walters. Working hypothesis , 2019, New Scientist.
[35] C. Gerfen,et al. Molecular cloning and expression of a D1 dopamine receptor linked to adenylyl cyclase activation. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[36] Phosphorylation by protein kinase C modulates agonist binding to striatal dopamine D2 receptors. , 1990, Biochemistry international.
[37] M. Caron,et al. Dopamine receptor subtypes: beyond the D1/D2 classification. , 1990, Trends in pharmacological sciences.
[38] Philip Seeman,et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine , 1991, Nature.
[39] Susan R. George,et al. Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1 , 1991, Nature.
[40] M. Caron,et al. Cloning, molecular characterization, and chromosomal assignment of a gene encoding a second D1 dopamine receptor subtype: differential expression pattern in rat brain compared with the D1A receptor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[41] D. Grandy,et al. Multiple human D5 dopamine receptor genes: a functional receptor and two pseudogenes. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[42] M. Martres,et al. Shorter variants of the D3 dopamine receptor produced through various patterns of alternative splicing. , 1991, Biochemical and biophysical research communications.
[43] M. Martres,et al. Localization and function of the D3 dopamine receptor. , 1992, Arzneimittel-Forschung.
[44] H. Niznik,et al. Dopamine receptor genes: new tools for molecular psychiatry. , 1992, Journal of psychiatry & neuroscience : JPN.
[45] D. Grandy,et al. Differential Sensitivity of the Short and Long Human Dopamine D2 Receptor Subtypes to Protein Kinase C , 1992, Journal of neurochemistry.
[46] P. Seeman,et al. Multiple dopamine D4 receptor variants in the human population , 1992, Nature.
[47] T. Dawson,et al. The G-protein-coupled receptor kinases beta ARK1 and beta ARK2 are widely distributed at synapses in rat brain , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[48] M. Martres,et al. Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor. , 1992, European journal of pharmacology.
[49] D. Sibley,et al. Molecular biology of dopamine receptors. , 1992, Trends in pharmacological sciences.
[50] M. Caron,et al. Recent advances in the molecular biology of dopamine receptors. , 1993, Annual review of neuroscience.
[51] P. Seeman,et al. Dopamine receptor pharmacology. , 1994, Trends in pharmacological sciences.
[52] D. Grandy,et al. Molecular diversity of the dopamine receptors. , 1993, Annual review of pharmacology and toxicology.
[53] James Inglese,et al. Protein kinases that phosphorylate activated G protein‐coupled receptors , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[54] P. Cohen,et al. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B , 1995, Nature.
[55] R. Palmiter,et al. Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic , 1995, Cell.
[56] A. Saiardi,et al. Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors , 1995, Nature.
[57] S. Morita,et al. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. , 1995, The Journal of pharmacology and experimental therapeutics.
[58] P. Greengard,et al. Dopamine- and cAMP-regulated phosphoprotein DARPP-32: phosphorylation of Ser-137 by casein kinase I inhibits dephosphorylation of Thr-34 by calcineurin. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[59] In vivo evidence for preferential role of dopamine D3 receptor in the presynaptic regulation of dopamine release but not synthesis. , 1996, European journal of pharmacology.
[60] N. Hiroi,et al. Regulation of ERK ( Extracellular Signal Regulated Kinase), Part of the Neurotrophin Signal Transduction Cascade, in the Rat Mesolimbic Dopamine System by Chronic Exposure to Morphine or Cocaine , 1996, The Journal of Neuroscience.
[61] M. Caron,et al. G-protein-coupled receptor regulation: role of G-protein-coupled receptor kinases and arrestins. , 1996, Canadian journal of physiology and pharmacology.
[62] H. Hamm,et al. Heterotrimeric G proteins. , 1996, Current opinion in cell biology.
[63] R. Mark Wightman,et al. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter , 1996, Nature.
[64] M. Caron,et al. Essential role of beta-adrenergic receptor kinase 1 in cardiac development and function. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[65] M. Andjelkovic,et al. Activation and phosphorylation of a pleckstrin homology domain containing protein kinase (RAC-PK/PKB) promoted by serum and protein phosphatase inhibitors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[66] S. R. Nash,et al. Differential Regulation of Dopamine D1A Receptor Responsiveness by Various G Protein-coupled Receptor Kinases (*) , 1996, The Journal of Biological Chemistry.
[67] P. Greengard,et al. Bidirectional Regulation of DARPP-32 Phosphorylation by Dopamine , 1997, The Journal of Neuroscience.
[68] J. Seidman,et al. β-Arrestin1 Knockout Mice Appear Normal but Demonstrate Altered Cardiac Responses to β-Adrenergic Stimulation , 1997 .
[69] D. Sibley,et al. D1-like dopaminergic activation of phosphoinositide hydrolysis is independent of D1A dopamine receptors: evidence from D1A knockout mice. , 1997, Molecular pharmacology.
[70] N. Andreasen. Improvement of negative symptoms: concepts, definition and assessment , 1997, International clinical psychopharmacology.
[71] J. Surmeier,et al. D2 dopamine receptors reduce N-type Ca2+ currents in rat neostriatal cholinergic interneurons through a membrane-delimited, protein-kinase-C-insensitive pathway. , 1997, Journal of neurophysiology.
[72] J. Seidman,et al. beta-Arrestin1 knockout mice appear normal but demonstrate altered cardiac responses to beta-adrenergic stimulation. , 1997, Circulation research.
[73] N. Dahmen,et al. Molecular cloning of rat G-protein-coupled receptor kinase 6 (GRK6) from brain tissue, and its mRNA expression in different brain regions and peripheral tissues. , 1997, Brain research. Molecular brain research.
[74] P. Willner. The mesolimbic dopamine system as a target for rapid antidepressant action , 1997, International clinical psychopharmacology.
[75] J. Thorner,et al. RGS Proteins and Signaling by Heterotrimeric G Proteins* , 1997, The Journal of Biological Chemistry.
[76] S. R. Nash,et al. Dopamine receptors: from structure to function. , 1998, Physiological reviews.
[77] R. Wightman,et al. Mechanisms of Amphetamine Action Revealed in Mice Lacking the Dopamine Transporter , 1998, The Journal of Neuroscience.
[78] K. Jellinger. Alzheimer-type lesions in Huntington's disease , 1998, Journal of Neural Transmission.
[79] R. Andrade,et al. Molecular characterization of human and rat RGS 9L, a novel splice variant enriched in dopamine target regions, and chromosomal localization of the RGS 9 gene. , 1998, Molecular pharmacology.
[80] Weifeng Yu,et al. Human Dopamine D3 and D2L Receptors Couple to Inward Rectifier Potassium Channels in Mammalian Cell Lines , 1998, Molecular and Cellular Neuroscience.
[81] A. Gilman,et al. Mammalian RGS Proteins: Barbarians at the Gate* , 1998, The Journal of Biological Chemistry.
[82] J. Arnt. Pharmacological differentation of classical and novel antipsychotics , 1998, International clinical psychopharmacology.
[83] Paul Greengard,et al. DARPP-32: Regulator of the Efficacy of Dopaminergic Neurotransmission , 1998 .
[84] E. Pugh,et al. Lifetime Regulation of G Protein–Effector Complex: Emerging Importance of RGS Proteins , 1998, Neuron.
[85] E D Levin,et al. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. , 1999, Science.
[86] L. Tsai,et al. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration , 1999, Nature.
[87] J. Granneman,et al. RGS mRNA Expression in Rat Striatum , 1999, Journal of neurochemistry.
[88] M. Caron,et al. Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. , 1999, Science.
[89] R. Gainetdinov,et al. Enhanced morphine analgesia in mice lacking beta-arrestin 2. , 1999, Science.
[90] R. Gainetdinov,et al. Muscarinic Supersensitivity and Impaired Receptor Desensitization in G Protein–Coupled Receptor Kinase 5–Deficient Mice , 1999, Neuron.
[91] R. Lefkowitz,et al. The GRK4 Subfamily of G Protein-coupled Receptor Kinases , 1999, The Journal of Biological Chemistry.
[92] Marc G Caron,et al. Mice with Reduced NMDA Receptor Expression Display Behaviors Related to Schizophrenia , 1999, Cell.
[93] K. Ito,et al. Dynamin and rab5 regulate GRK2-dependent internalization of dopamine D2 receptors. , 1999, European journal of biochemistry.
[94] P. Greengard,et al. Beyond the Dopamine Receptor: Review the DARPP-32/Protein Phosphatase-1 Cascade , 1999 .
[95] D. Chuang,et al. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[96] P. Greengard,et al. Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons , 1999, Nature.
[97] D. Sibley,et al. New insights into dopaminergic receptor function using antisense and genetically altered animals. , 1999, Annual review of pharmacology and toxicology.
[98] R. Lefkowitz,et al. Heptahelical Receptor Signaling: Beyond the G Protein Paradigm , 1999, The Journal of cell biology.
[99] R. Gainetdinov,et al. Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. , 2000, Nature.
[100] Marc G. Caron,et al. μ-Opioid receptor desensitization by β-arrestin-2 determines morphine tolerance but not dependence , 2000, Nature.
[101] C. Gerfen. Molecular effects of dopamine on striatal-projection pathways , 2000, Trends in Neurosciences.
[102] E. Borrelli,et al. Structure and function of dopamine receptors , 2000, Neuroscience & Biobehavioral Reviews.
[103] Alessandro Usiello,et al. Distinct functions of the two isoforms of dopamine D2 receptors , 2000, Nature.
[104] H. V. Van Tol,et al. Polymorphisms in dopamine receptors: what do they tell us? , 2000, European journal of pharmacology.
[105] J. Woodgett,et al. Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation , 2000, Nature.
[106] J. Bargas,et al. D2 Dopamine Receptors in Striatal Medium Spiny Neurons Reduce L-Type Ca2+ Currents and Excitability via a Novel PLCβ1–IP3–Calcineurin-Signaling Cascade , 2000, The Journal of Neuroscience.
[107] M. Besson,et al. Involvement of the Extracellular Signal-Regulated Kinase Cascade for Cocaine-Rewarding Properties , 2000, The Journal of Neuroscience.
[108] Yu Tian Wang,et al. Direct protein–protein coupling enables cross-talk between dopamine D5 and γ-aminobutyric acid A receptors , 2000, Nature.
[109] J. Woodgett,et al. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. , 2000, Nature.
[110] W. Maragos,et al. Neuronal cell death in Huntington’s disease: a potential role for dopamine , 2000, Trends in Neurosciences.
[111] Fei Xu,et al. Mice lacking the norepinephrine transporter are supersensitive to psychostimulants , 2000, Nature Neuroscience.
[112] A. Aperia. Intrarenal dopamine: a key signal in the interactive regulation of sodium metabolism. , 2000, Annual review of physiology.
[113] S. Ferguson,et al. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. , 2001, Pharmacological reviews.
[114] P. Cohen,et al. GSK3 takes centre stage more than 20 years after its discovery. , 2001, The Biochemical journal.
[115] T. Kohout,et al. beta-Arrestin 1 and 2 differentially regulate heptahelical receptor signaling and trafficking. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[116] M. Caron,et al. Molecular Determinants Underlying the Formation of Stable Intracellular G Protein-coupled Receptor-β-Arrestin Complexes after Receptor Endocytosis* , 2001, The Journal of Biological Chemistry.
[117] J. Woodgett,et al. PKB/AKT: functional insights from genetic models , 2001, Nature Reviews Molecular Cell Biology.
[118] A Carlsson,et al. A Paradigm Shift in Brain Research , 2001, Science.
[119] A Carlsson,et al. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. , 2001, Annual review of pharmacology and toxicology.
[120] Li-Huei Tsai,et al. A decade of CDK5 , 2001, Nature Reviews Molecular Cell Biology.
[121] M. Caron,et al. Differential Regulation of the Dopamine D2and D3 Receptors by G Protein-coupled Receptor Kinases and β-Arrestins* , 2001, The Journal of Biological Chemistry.
[122] James R. Woodgett,et al. Judging a Protein by More Than Its Name: GSK-3 , 2001, Science's STKE.
[123] J. Julien,et al. Deregulation of Cdk5 in a Mouse Model of ALS Toxicity Alleviated by Perikaryal Neurofilament Inclusions , 2001, Neuron.
[124] D. Standaert,et al. Dopamine D1 Receptor-Dependent Trafficking of Striatal NMDA Glutamate Receptors to the Postsynaptic Membrane , 2001, The Journal of Neuroscience.
[125] S. Ammon,et al. Distribution of G-protein-coupled receptor kinase (GRK) isoforms 2, 3, 5 and 6 mRNA in the rat brain. , 2001, Brain research. Molecular brain research.
[126] P. Cohen,et al. The renaissance of GSK3 , 2001, Nature Reviews Molecular Cell Biology.
[127] P. Greengard. The neurobiology of slow synaptic transmission. , 2001, Science.
[128] P. Greengard,et al. Effects of chronic exposure to cocaine are regulated by the neuronal protein Cdk5 , 2001, Nature.
[129] Xiaohua Li,et al. Regulation of Akt and glycogen synthase kinase-3β phosphorylation by sodium valproate and lithium , 2002, Neuropharmacology.
[130] N. Lavine,et al. G Protein-coupled Receptors Form Stable Complexes with Inwardly Rectifying Potassium Channels and Adenylyl Cyclase* , 2002, The Journal of Biological Chemistry.
[131] Yu Tian Wang,et al. Dual Regulation of NMDA Receptor Functions by Direct Protein-Protein Interactions with the Dopamine D1 Receptor , 2002, Cell.
[132] M. Caron,et al. beta-Arrestin/AP-2 interaction in G protein-coupled receptor internalization: identification of a beta-arrestin binging site in beta 2-adaptin. , 2002, The Journal of biological chemistry.
[133] Marc Laruelle,et al. Neuroreceptor imaging in psychiatric disorders , 2002, Annals of nuclear medicine.
[134] Paul Greengard,et al. Dopamine enhancement of NMDA currents in dissociated medium-sized striatal neurons: role of D1 receptors and DARPP-32. , 2002, Journal of neurophysiology.
[135] Paul Greengard,et al. Evidence for decreased DARPP-32 in the prefrontal cortex of patients with schizophrenia. , 2002, Archives of general psychiatry.
[136] C. Tamminga,et al. Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis. , 2002, Current drug targets. CNS and neurological disorders.
[137] P. Goldman-Rakic,et al. Interaction with Neuronal Calcium Sensor NCS-1 Mediates Desensitization of the D2 Dopamine Receptor , 2002, The Journal of Neuroscience.
[138] Antiemetic therapy. , 2002, Critical reviews in oncology/hematology.
[139] R. Lefkowitz,et al. The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. , 2002, Journal of cell science.
[140] M. Caron,et al. Endocytosis of G protein-coupled receptors: roles of G protein-coupled receptor kinases and ß-arrestin proteins , 2002, Progress in Neurobiology.
[141] R. Wightman,et al. Dopamine autoreceptor regulation of release and uptake in mouse brain slices in the absence of D3 receptors , 2002, Neuroscience.
[142] A. Zapata,et al. D3 receptor ligands modulate extracellular dopamine clearance in the nucleus accumbens , 2002, Journal of neurochemistry.
[143] M. Caron,et al. β-Arrestin/AP-2 Interaction in G Protein-coupled Receptor Internalization , 2002, The Journal of Biological Chemistry.
[144] J. Benovic,et al. Arrestin2 and arrestin3 are differentially expressed in the rat brain during postnatal development , 2002, Neuroscience.
[145] Wei Wang,et al. G protein-coupled receptor kinase 4 gene variants in human essential hypertension , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[146] P. Greengard,et al. Involvement of DARPP-32 phosphorylation in the stimulant action of caffeine , 2002, Nature.
[147] P. Greengard,et al. Topographical Assessment of Ethological and Dopamine Receptor Agonist-Induced Behavioral Phenotype in Mutants with Congenic DARPP-32 ‘Knockout’ , 2003, Neuropsychopharmacology.
[148] P. Greengard,et al. Diverse Psychotomimetics Act Through a Common Signaling Pathway , 2003, Science.
[149] J. Julien,et al. Peripherin‐mediated death of motor neurons rescued by overexpression of neurofilament NF‐H proteins , 2003, Journal of neurochemistry.
[150] H. V. Tol,et al. The dopamine D4 receptors and mechanisms of antipsychotic atypicality , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[151] P. Greengard,et al. Opposite regulation by typical and atypical anti‐psychotics of ERK1/2, CREB and Elk‐1 phosphorylation in mouse dorsal striatum , 2003, Journal of neurochemistry.
[152] P. Spano,et al. Regulation of Dopamine D1 Receptor Trafficking and Desensitization by Oligomerization with Glutamate N-Methyl-D-aspartate Receptors* , 2003, Journal of Biological Chemistry.
[153] Susumu Tonegawa,et al. Evidence for association of schizophrenia with genetic variation in the 8p21.3 gene, PPP3CC, encoding the calcineurin gamma subunit , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[154] Roberto Malinow,et al. PKA phosphorylation of AMPA receptor subunits controls synaptic trafficking underlying plasticity , 2003, Nature Neuroscience.
[155] Hongkui Zeng,et al. Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[156] Marc G Caron,et al. Dopaminergic Supersensitivity in G Protein-Coupled Receptor Kinase 6-Deficient Mice , 2003, Neuron.
[157] J. Leysen,et al. Striatal gene expression of RGS2 and RGS4 is specifically mediated by dopamine D1 and D2 receptors: clues for RGS2 and RGS4 functions , 2003, Journal of neurochemistry.
[158] R. Mailman,et al. Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology , 2003, Neuropsychopharmacology.
[159] T. Sotnikova,et al. Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[160] R. Lefkowitz,et al. Multifaceted roles of β-arrestins in the regulation of seven-membrane-spanning receptor trafficking and signalling , 2003 .
[161] D. Kögel,et al. The amyloid precursor protein protects PC12 cells against endoplasmic reticulum stress‐induced apoptosis , 2003, Journal of neurochemistry.
[162] Johannes Schwarz,et al. RGS9 Modulates Dopamine Signaling in the Basal Ganglia , 2003, Neuron.
[163] H. Dohlman,et al. RGS proteins: G protein-coupled receptors meet their match. , 2003, Assay and drug development technologies.
[164] Shiaoching Gong,et al. A gene expression atlas of the central nervous system based on bacterial artificial chromosomes , 2003, Nature.
[165] P. Goldman-Rakic,et al. Dopamine receptor-interacting proteins: the Ca(2+) connection in dopamine signaling. , 2003, Trends in pharmacological sciences.
[166] S. Detera-Wadleigh,et al. Analysis of a cluster of polymorphisms in AKT1 gene in bipolar pedigrees: a family-based association study , 2003, Neuroscience Letters.
[167] Marc G Caron,et al. Enhanced Rewarding Properties of Morphine, but not Cocaine, in βarrestin-2 Knock-Out Mice , 2003, The Journal of Neuroscience.
[168] C. Phiel,et al. Inhibitory Phosphorylation of Glycogen Synthase Kinase-3 (GSK-3) in Response to Lithium , 2003, Journal of Biological Chemistry.
[169] M. Caron,et al. Comparative Studies of Molecular Mechanisms of Dopamine D2 and D3 Receptors for the Activation of Extracellular Signal-regulated Kinase* , 2004, Journal of Biological Chemistry.
[170] D. Sibley,et al. Protein Kinase C Mediates Phosphorylation, Desensitization, and Trafficking of the D2 Dopamine Receptor* , 2004, Journal of Biological Chemistry.
[171] D. Surmeier,et al. RGS9-2 modulates D2 dopamine receptor-mediated Ca2+ channel inhibition in rat striatal cholinergic interneurons. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[172] J. Woodgett,et al. Glycogen Synthase Kinase-3β Haploinsufficiency Mimics the Behavioral and Molecular Effects of Lithium , 2004, The Journal of Neuroscience.
[173] D. Sibley,et al. Protein Kinase C Mediates Phosphorylation , Desensitization and Trafficking of the D 2 Dopamine Receptor , 2004 .
[174] M. Roh,et al. In Vivo Regulation of Glycogen Synthase Kinase-3β (GSK3β) by Serotonergic Activity in Mouse Brain , 2004, Neuropsychopharmacology.
[175] J. Leysen,et al. Dopamine receptor‐mediated regulation of RGS2 and RGS4 mRNA differentially depends on ascending dopamine projections and time , 2004, The European journal of neuroscience.
[176] B. Roth,et al. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia , 2004, Nature Reviews Drug Discovery.
[177] P. Greengard,et al. Ethologically Based Resolution of D2-Like Dopamine Receptor Agonist-versus Antagonist-Induced Behavioral Topography in Dopamine- and Adenosine 3′,5′-Monophosphate-Regulated Phosphoprotein of 32 kDa “Knockout” Mutants Congenic on the C57BL/6 Genetic Background , 2004, Journal of Pharmacology and Experimental Therapeutics.
[178] P. Greengard,et al. Cyclin-dependent kinase 5 regulates dopaminergic and glutamatergic transmission in the striatum , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[179] Marc G Caron,et al. Desensitization of G protein-coupled receptors and neuronal functions. , 2004, Annual review of neuroscience.
[180] B. O'dowd,et al. Dopamine D1 and D2 Receptor Co-activation Generates a Novel Phospholipase C-mediated Calcium Signal* , 2004, Journal of Biological Chemistry.
[181] E. Borrelli,et al. Wheel running use in dopamine D2L receptor knockout mice , 2004, Neuroscience Letters.
[182] Carlos Cepeda,et al. Genetic mouse models of Huntington's and Parkinson's diseases: illuminating but imperfect , 2004, Trends in Neurosciences.
[183] A. Serretti,et al. A glycogen synthase kinase 3-β promoter gene single nucleotide polymorphism is associated with age at onset and response to total sleep deprivation in bipolar depression , 2004, Neuroscience Letters.
[184] H. Manji,et al. AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. , 2004, The international journal of neuropsychopharmacology.
[185] J. Lindenmayer,et al. Pharmacological treatment strategies for schizophrenia , 2004, Expert review of neurotherapeutics.
[186] Paul Witkovsky,et al. Dopamine and retinal function , 2004, Documenta Ophthalmologica.
[187] V. Gurevich,et al. The molecular acrobatics of arrestin activation. , 2004, Trends in pharmacological sciences.
[188] J. Seamans,et al. Dopamine Receptor Signaling , 2004, Journal of receptor and signal transduction research.
[189] M. Karayiorgou,et al. Convergent evidence for impaired AKT1-GSK3β signaling in schizophrenia , 2004, Nature Genetics.
[190] F. Lee,et al. Regulation of Dopamine D1 Receptor Function by Physical Interaction with the Nmda Receptors Functional Interactions between Dopamine D1-like Receptors and Nmda Subtype Glutamate Receptors Have Been Implicated in the Maintenance of Normal Brain Activity and Neurological Dysfunction. Although Modulati , 2022 .
[191] M. Roh,et al. In vivo regulation of glycogen synthase kinase-3beta (GSK3beta) by serotonergic activity in mouse brain. , 2004, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.
[192] Patricia S. Goldman-Rakic,et al. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction , 2004, Psychopharmacology.
[193] Angus C Nairn,et al. DARPP-32: an integrator of neurotransmission. , 2004, Annual review of pharmacology and toxicology.
[194] R. Lefkowitz,et al. Differential Kinetic and Spatial Patterns of β-Arrestin and G Protein-mediated ERK Activation by the Angiotensin II Receptor* , 2004, Journal of Biological Chemistry.
[195] P. Greengard,et al. The neurobiology of dopamine signaling , 2002, European Psychiatry.
[196] Zhen Yan,et al. Potentiation of NMDA receptor currents by dopamine D1 receptors in prefrontal cortex. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[197] Ying Xia,et al. Cocaine-Induced Intracellular Signaling and Gene Expression Are Oppositely Regulated by the Dopamine D1 and D3 Receptors , 2004, The Journal of Neuroscience.
[198] M. Caron,et al. Relative opioid efficacy is determined by the complements of the G protein-coupled receptor desensitization machinery. , 2004, Molecular pharmacology.
[199] T. Sotnikova,et al. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[200] A. Sidhu,et al. D1 Dopamine Receptor Mediates Dopamine-induced Cytotoxicity via the ERK Signal Cascade* , 2004, Journal of Biological Chemistry.
[201] RGS9-2 modulates D 2 dopamine receptor-mediated Ca 2+ channel inhibition in rat striatal cholinergic interneurons , 2004 .
[202] Marc G Caron,et al. Identification of PSD-95 as a Regulator of Dopamine-Mediated Synaptic and Behavioral Plasticity , 2004, Neuron.
[203] G. Forloni,et al. Genotype-Dependent Activity of Tryptophan Hydroxylase-2 Determines the Response to Citalopram in a Mouse Model of Depression , 2005, The Journal of Neuroscience.
[204] Y. Shaham,et al. Central amygdala ERK signaling pathway is critical to incubation of cocaine craving , 2005, Nature Neuroscience.
[205] J. Girault,et al. Parsing Molecular and Behavioral Effects of Cocaine in Mitogen- and Stress-Activated Protein Kinase-1-Deficient Mice , 2005, The Journal of Neuroscience.
[206] R. Lefkowitz,et al. Seven-Transmembrane Receptor Signaling Through β-Arrestin , 2005, Science's STKE.
[207] R. Gainetdinov,et al. G Protein-coupled Receptor Kinase Regulates Dopamine D3 Receptor Signaling by Modulating the Stability of a Receptor-Filamin-β-Arrestin Complex , 2005, Journal of Biological Chemistry.
[208] J. Girault,et al. Role of the ERK pathway in psychostimulant-induced locomotor sensitization , 2006, BMC Neuroscience.
[209] Angus C Nairn,et al. Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[210] K. Neve,et al. Dopamine D2 receptor stimulation of mitogen‐activated protein kinases mediated by cell type‐dependent transactivation of receptor tyrosine kinases , 2005, Journal of neurochemistry.
[211] P. Greengard,et al. Cannabinoid Action Depends on Phosphorylation of Dopamine- and cAMP-Regulated Phosphoprotein of 32 kDa at the Protein Kinase A Site in Striatal Projection Neurons , 2005, The Journal of Neuroscience.
[212] I. Lucki,et al. Strain-dependent antidepressant-like effects of citalopram in the mouse tail suspension test , 2005, Psychopharmacology.
[213] W. Wetsel,et al. Dopamine-Independent Locomotor Actions of Amphetamines in a Novel Acute Mouse Model of Parkinson Disease , 2005, PLoS biology.
[214] R. Lefkowitz,et al. Seven-transmembrane receptor signaling through beta-arrestin. , 2005, Science's STKE : signal transduction knowledge environment.
[215] N. Rajakumar,et al. Antipsychotics alter the protein expression levels of β-catenin and GSK-3 in the rat medial prefrontal cortex and striatum , 2005, Biological Psychiatry.
[216] Audrey Claing,et al. Novel roles for arrestins in G protein-coupled receptor biology and drug discovery. , 2005, Current opinion in drug discovery & development.
[217] L. Kaczmarek,et al. Extracellular signal‐regulated kinases (ERKs) modulate cocaine‐induced gene expression in the mouse amygdala , 2005, The European journal of neuroscience.
[218] Philip Seeman,et al. Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[219] J. Marshall,et al. Molecular Substrates for Retrieval and Reconsolidation of Cocaine-Associated Contextual Memory , 2005, Neuron.
[220] Johannes Schwarz,et al. D2 Dopamine Receptors Colocalize Regulator of G-Protein Signaling 9-2 (RGS9-2) via the RGS9 DEP Domain, and RGS9 Knock-Out Mice Develop Dyskinesias Associated with Dopamine Pathways , 2005, The Journal of Neuroscience.
[221] T. Sotnikova,et al. An Akt/β-Arrestin 2/PP2A Signaling Complex Mediates Dopaminergic Neurotransmission and Behavior , 2005, Cell.
[222] A. Russo-Neustadt,et al. Exercise activates the phosphatidylinositol 3-kinase pathway. , 2005, Brain research. Molecular brain research.
[223] J. Waddington,et al. Phenotypic studies on dopamine receptor subtype and associated signal transduction mutants: insights and challenges from 10 years at the psychopharmacology–molecular biology interface , 2005, Psychopharmacology.
[224] J. Lieberman,et al. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs , 2005, Molecular Psychiatry.
[225] V. V. Gurevich,et al. l-DOPA reverses the MPTP-induced elevation of the arrestin2 and GRK6 expression and enhanced ERK activation in monkey brain , 2005, Neurobiology of Disease.
[226] Sang Ki Park,et al. Par-4 Links Dopamine Signaling and Depression , 2005, Cell.
[227] M. Scarselli,et al. The impact of G‐protein‐coupled receptor hetero‐oligomerization on function and pharmacology , 2005, The FEBS journal.
[228] Gilberto Fisone,et al. Increased D1 dopamine receptor signaling in levodopa‐induced dyskinesia , 2005, Annals of neurology.
[229] P. Pavlidis,et al. Akt1 deficiency affects neuronal morphology and predisposes to abnormalities in prefrontal cortex functioning , 2006, Proceedings of the National Academy of Sciences.
[230] Michel Cyr,et al. The FASEB Journal • FJ Express Full-Length Article Dopamine enhances motor and neuropathological consequences of polyglutamine expanded huntingtin , 2022 .
[231] K. Neve,et al. Modulation of D2R-NR2B Interactions in Response to Cocaine , 2006, Neuron.
[232] T. Steckler,et al. Transgenic Mice Overexpressing Glycogen Synthase Kinase 3β: A Putative Model of Hyperactivity and Mania , 2006, The Journal of Neuroscience.
[233] S. Hyman,et al. Neural mechanisms of addiction: the role of reward-related learning and memory. , 2006, Annual review of neuroscience.
[234] P. Greengard,et al. Cocaine Self-Administration in Mice Is Inversely Related to Phosphorylation at Thr34 (Protein Kinase A Site) and Ser130 (Kinase CK1 Site) of DARPP-32 , 2006, The Journal of Neuroscience.
[235] E. Borrelli,et al. Impaired light masking in dopamine D2 receptor–null mice , 2006, Nature Neuroscience.
[236] A. Colao,et al. Drug Insight: cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women , 2006, Nature Clinical Practice Endocrinology &Metabolism.
[237] Thomas E. Nichols,et al. Impact of complex genetic variation in COMT on human brain function , 2006, Molecular Psychiatry.
[238] J. McGinty,et al. Acute amphetamine down‐regulates RGS4 mRNA and protein expression in rat forebrain: distinct roles of D1 and D2 dopamine receptors , 2006, Journal of neurochemistry.
[239] M. Gershon,et al. Physiological Modulation of Intestinal Motility by Enteric Dopaminergic Neurons and the D2 Receptor: Analysis of Dopamine Receptor Expression, Location, Development, and Function in Wild-Type and Knock-Out Mice , 2006, The Journal of Neuroscience.
[240] J. Baik,et al. The Dopamine D2 Receptor Regulates the Development of Dopaminergic Neurons via Extracellular Signal-Regulated Kinase and Nurr1 Activation , 2006, The Journal of Neuroscience.
[241] E. Borrelli,et al. Signaling mediated by the dopamine D2 receptor potentiates circadian regulation by CLOCK:BMAL1. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[242] Mario Tiberi,et al. Molecular characterization of dopamine D2 receptor isoforms tagged with green fluorescent protein , 2006, Molecular biotechnology.
[243] T. Sotnikova,et al. Paradoxical Striatal Cellular Signaling Responses to Psychostimulants in Hyperactive Mice* , 2006, Journal of Biological Chemistry.
[244] Sarah A. J. Reading,et al. Neurobiology of Schizophrenia , 2006, Neuron.
[245] J. Qin,et al. SIN1/MIP1 Maintains rictor-mTOR Complex Integrity and Regulates Akt Phosphorylation and Substrate Specificity , 2006, Cell.
[246] J. Girault,et al. Plasticity-Associated Gene Krox24/Zif268 Is Required for Long-Lasting Behavioral Effects of Cocaine , 2006, The Journal of Neuroscience.
[247] Dopamine receptors oppositely regulate cocaine-induced transcription factor CREB activation. , 2006, Nan fang yi ke da xue xue bao = Journal of Southern Medical University.
[248] P. Seeman. Targeting the dopamine D2 receptor in schizophrenia , 2006, Expert opinion on therapeutic targets.
[249] J. Mink,et al. Neurobiology of basal ganglia and Tourette syndrome: basal ganglia circuits and thalamocortical outputs. , 2006, Advances in neurology.
[250] E. Cook,et al. Association between the Casein Kinase 1 Epsilon Gene Region and Subjective Response to D-Amphetamine , 2006, Neuropsychopharmacology.
[251] D. Sibley,et al. The D1 Dopamine Receptor Is Constitutively Phosphorylated by G Protein-Coupled Receptor Kinase 4 , 2006, Molecular Pharmacology.
[252] E. Bézard,et al. The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. , 2006, CNS & neurological disorders drug targets.
[253] Arthur Christopoulos,et al. Functional Selectivity and Classical Concepts of Quantitative Pharmacology , 2007, Journal of Pharmacology and Experimental Therapeutics.
[254] B. O'dowd,et al. D1–D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum , 2007, Proceedings of the National Academy of Sciences.
[255] Andreas Meyer-Lindenberg,et al. Genetic evidence implicating DARPP-32 in human frontostriatal structure, function, and cognition. , 2007, The Journal of clinical investigation.
[256] G. He,et al. An association study between PPP1R1B gene and schizophrenia in the Chinese population , 2007, Progress in Neuro-psychopharmacology and Biological Psychiatry.
[257] H. Meziane,et al. Absence of dopamine D2 receptors unmasks an inhibitory control over the brain circuitries activated by cocaine , 2007, Proceedings of the National Academy of Sciences.
[258] M. Caron,et al. Roles of protein kinase C and actin-binding protein 280 in the regulation of intracellular trafficking of dopamine D3 receptor. , 2007, Molecular endocrinology.
[259] R. Mailman. GPCR functional selectivity has therapeutic impact. , 2007, Trends in pharmacological sciences.
[260] G. Collingridge,et al. LTP Inhibits LTD in the Hippocampus via Regulation of GSK3β , 2007, Neuron.
[261] C. Aiken. Pramipexole in psychiatry: a systematic review of the literature. , 2007, The Journal of clinical psychiatry.
[262] S. Iversen,et al. Dopamine: 50 years in perspective , 2007, Trends in Neurosciences.
[263] Denis Hervé,et al. ERK2: a logical AND gate critical for drug-induced plasticity? , 2007, Current opinion in pharmacology.
[264] R. Gainetdinov,et al. The Akt-GSK-3 signaling cascade in the actions of dopamine. , 2007, Trends in pharmacological sciences.
[265] Jian-Guo Chen,et al. Activation of Glycogen Synthase Kinase-3 Inhibits Long-Term Potentiation with Synapse-Associated Impairments , 2007, The Journal of Neuroscience.
[266] A. Banday,et al. Insulin causes renal dopamine D1 receptor desensitization via GRK2-mediated receptor phosphorylation involving phosphatidylinositol 3-kinase and protein kinase C. , 2007, American journal of physiology. Renal physiology.
[267] M. Leboyer,et al. Association between the PPP3CC gene, coding for the calcineurin gamma catalytic subunit, and bipolar disorder , 2008, Behavioral and Brain Functions.
[268] B. Dean,et al. Consistent with dopamine supersensitivity, RGS9 expression is diminished in the amphetamine‐treated animal model of schizophrenia and in postmortem schizophrenia brain , 2007, Synapse.
[269] S. Grant,et al. Inhibition of the Dopamine D1 Receptor Signaling by PSD-95*♦ , 2007, Journal of Biological Chemistry.
[270] Qin Li,et al. RGS9–2 Negatively Modulates l-3,4-Dihydroxyphenylalanine-Induced Dyskinesia in Experimental Parkinson's Disease , 2007, The Journal of Neuroscience.
[271] A. Malafosse,et al. Alteration in Kinase Activity But Not in Protein Levels of Protein Kinase B and Glycogen Synthase Kinase-3β in Ventral Prefrontal Cortex of Depressed Suicide Victims , 2007, Biological Psychiatry.
[272] G. Di Chiara,et al. Reward system and addiction: what dopamine does and doesn't do. , 2007, Current opinion in pharmacology.
[273] U. Bonuccelli,et al. Role of dopamine agonists in Parkinson’s disease: an update , 2007, Expert review of neurotherapeutics.
[274] P. Albert,et al. Differential desensitization of dopamine D2 receptor isoforms by protein kinase C: the importance of receptor phosphorylation and pseudosubstrate sites. , 2007, European journal of pharmacology.
[275] D. Sibley,et al. D1 and D2 Dopamine Receptor Expression Is Regulated by Direct Interaction with the Chaperone Protein Calnexin* , 2007, Journal of Biological Chemistry.
[276] T. Sotnikova,et al. Regulation of Akt Signaling by D2 and D3 Dopamine Receptors In Vivo , 2007, The Journal of Neuroscience.
[277] Zhen Yan,et al. Glycogen Synthase Kinase 3 Regulates N-Methyl-d-aspartate Receptor Channel Trafficking and Function in Cortical Neurons , 2007, Molecular Pharmacology.
[278] B. J. Casey,et al. Etiologic Subtypes of Attention-Deficit/Hyperactivity Disorder: Brain Imaging, Molecular Genetic and Environmental Factors and the Dopamine Hypothesis , 2007, Neuropsychology Review.
[279] C. Hoogenraad,et al. The postsynaptic architecture of excitatory synapses: a more quantitative view. , 2007, Annual review of biochemistry.
[280] T. Asada,et al. Immunohistochemical and immunoblot analysis of Dopamine and cyclic AMP-regulated phosphoprotein, relative molecular mass 32,000 (DARPP-32) in the prefrontal cortex of subjects with schizophrenia and bipolar disorder , 2007, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[281] P. Lewi,et al. Forty Years of Antipsychotic Drug Research – from Haloperidol to Paliperidone – with Dr. Paul Janssen , 2007, Arzneimittelforschung.
[282] C. Carson. Central nervous system-acting agents and the treatment of erectile and sexual dysfunction , 2007, Current urology reports.
[283] K. Roth,et al. Regulation of mouse brain glycogen synthase kinase-3 by atypical antipsychotics. , 2007, The international journal of neuropsychopharmacology.
[284] R. Gainetdinov,et al. Physiological roles of G protein-coupled receptor kinases and arrestins. , 2007, Annual review of physiology.
[285] J. Beaulieu. Not only lithium: regulation of glycogen synthase kinase-3 by antipsychotics and serotonergic drugs. , 2007, The international journal of neuropsychopharmacology.
[286] Paul Greengard,et al. Critical Involvement of cAMP/DARPP-32 and Extracellular Signal-Regulated Protein Kinase Signaling in l-DOPA-Induced Dyskinesia , 2007, The Journal of Neuroscience.
[287] S. Faraone,et al. More evidence supports the association of PPP3CC with schizophrenia , 2007, Molecular Psychiatry.
[288] M. Bouvier,et al. The evasive nature of drug efficacy: implications for drug discovery. , 2007, Trends in pharmacological sciences.
[289] R. Kerwin,et al. A dopamine D2 receptor gene-related polymorphism is associated with schizophrenia in a Spanish population isolate , 2007, Psychiatric genetics.
[290] M. Iyo,et al. Possible association of β‐arrestin 2 gene with methamphetamine use disorder, but not schizophrenia , 2007, Genes, brain, and behavior.
[291] T. Sotnikova,et al. Genetic NMDA Receptor Deficiency Disrupts Acute and Chronic Effects of Cocaine but not Amphetamine , 2008, Neuropsychopharmacology.
[292] C. Bergson,et al. A Crucial Role for cAMP and Protein Kinase A in D1 Dopamine Receptor Regulated Intracellular Calcium Transients , 2008, Neurosignals.
[293] R. Gainetdinov,et al. Antagonism of dopamine D2 receptor/β-arrestin 2 interaction is a common property of clinically effective antipsychotics , 2008, Proceedings of the National Academy of Sciences.
[294] K. Dalby,et al. Haloperidol and Clozapine Differentially Affect the Expression of Arrestins, Receptor Kinases, and Extracellular Signal-Regulated Kinase Activation , 2008, Journal of Pharmacology and Experimental Therapeutics.
[295] T. Yoshikawa,et al. Genetic analysis of the gene coding for DARPP-32 (PPP1R1B) in Japanese patients with schizophrenia or bipolar disorder , 2008, Schizophrenia Research.
[296] G. Sanger,et al. Development of drugs for gastrointestinal motor disorders: translating science to clinical need , 2008, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.
[297] B. MacVicar,et al. D1 Receptors Physically Interact with N-Type Calcium Channels to Regulate Channel Distribution and Dendritic Calcium Entry , 2008, Neuron.
[298] Andrew B. Singleton,et al. Association between AKT1 gene and Parkinson's disease: A protective haplotype , 2008, Neuroscience Letters.
[299] G. Zamponi,et al. D2 dopamine receptors interact directly with N-type calcium channels and regulate channel surface expression levels , 2008, Channels.
[300] W. Yao,et al. Dopaminergic signaling in dendritic spines. , 2008, Biochemical pharmacology.
[301] Vladimir I. Vladimirov,et al. AKT1 Is Associated with Schizophrenia Across Multiple Symptom Dimensions in the Irish Study of High Density Schizophrenia Families , 2008, Biological Psychiatry.
[302] M. Caron,et al. Looking at lithium: molecular moods and complex behaviour. , 2008, Molecular interventions.
[303] M. Cyr,et al. Dopamine D1 receptor–mediated aggregation of N-terminal fragments of mutant huntingtin and cell death in a neuroblastoma cell line , 2008, Neuroscience.
[304] Paolo Sassone-Corsi,et al. Decoding the Epigenetic Language of Neuronal Plasticity , 2008, Neuron.
[305] Ya-Mei Bai,et al. The coding‐synonymous polymorphism rs1045280 (Ser280Ser) in β‐arrestin 2 (ARRB2) gene is associated with tardive dyskinesia in Chinese patients with schizophrenia , 2008, European journal of neurology.
[306] M. Iyo,et al. Association Study of the Calcineurin A Gamma Subunit Gene (PPP3CC) and Methamphetamine‐Use Disorder in a Japanese Population , 2008, Annals of the New York Academy of Sciences.
[307] G. Collingridge,et al. The role of GSK‐3 in synaptic plasticity , 2008, British journal of pharmacology.
[308] B. Gloss,et al. Drd1a-tdTomato BAC Transgenic Mice for Simultaneous Visualization of Medium Spiny Neurons in the Direct and Indirect Pathways of the Basal Ganglia , 2008, The Journal of Neuroscience.
[309] P. Greengard,et al. A Translational Profiling Approach for the Molecular Characterization of CNS Cell Types , 2008, Cell.
[310] D. Sibley,et al. Ethanol Regulation of D1 Dopamine Receptor Signaling is Mediated by Protein Kinase C in an Isozyme-Specific Manner , 2008, Neuropsychopharmacology.
[311] Paul Greengard,et al. A phosphatase cascade by which rewarding stimuli control nucleosomal response , 2008, Nature.
[312] Arun K Shukla,et al. Distinct conformational changes in β-arrestin report biased agonism at seven-transmembrane receptors , 2008, Proceedings of the National Academy of Sciences.
[313] J. Varon. Treatment of acute severe hypertension: current and newer agents. , 2008, Drugs.
[314] R. Rodriguiz,et al. Role of GSK3β in behavioral abnormalities induced by serotonin deficiency , 2008, Proceedings of the National Academy of Sciences.
[315] J. Staessen,et al. Blood Pressure and Renal Sodium Handling in Relation to Genetic Variation in the DRD1 Promoter and GRK4 , 2008, Hypertension.
[316] H. Manji,et al. Kinases as drug targets in the treatment of bipolar disorder. , 2008, Drug discovery today.
[317] L. Bertram. Genetic research in schizophrenia: new tools and future perspectives. , 2008, Schizophrenia bulletin.
[318] A. Meyer-Lindenberg,et al. Genetic variation in AKT1 is linked to dopamine-associated prefrontal cortical structure and function in humans. , 2008, The Journal of clinical investigation.
[319] J. Benovic,et al. Altered expression and subcellular distribution of GRK subtypes in the dopamine‐depleted rat basal ganglia is not normalized by l‐DOPA treatment , 2008, Journal of neurochemistry.
[320] J. Javitch,et al. Recruitment of β-arrestin2 to the dopamine D2 receptor: Insights into anti-psychotic and anti-parkinsonian drug receptor signaling , 2008, Neuropharmacology.
[321] Donard S Dwyer,et al. Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection , 2008, Pharmacological Reviews.
[322] Paul Greengard,et al. Cell type–specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs , 2008, Nature Neuroscience.
[323] J. Kennedy,et al. Reduced prefrontal cortex DARPP-32 mRNA in completed suicide victims with schizophrenia , 2008, Schizophrenia Research.
[324] M. Zhuo,et al. FMRP Acts as a Key Messenger for Dopamine Modulation in the Forebrain , 2008, Neuron.
[325] Emerging drugs for schizophrenia. , 2008, Expert opinion on emerging drugs.
[326] R. Rodriguiz,et al. Reply to Belmaker et al.: GSK3β haploinsufficiency results in lithium-like effects in the forced-swim test , 2008, Proceedings of the National Academy of Sciences.
[327] R. Rodriguiz,et al. A β-arrestin 2 Signaling Complex Mediates Lithium Action on Behavior , 2008, Cell.
[328] P. S. Klein,et al. Validating GSK3 as an in vivo target of lithium action. , 2009, Biochemical Society transactions.
[329] P. Greengard,et al. Inhibition of mTOR Signaling in Parkinson’s Disease Prevents l-DOPA–Induced Dyskinesia , 2009, Science Signaling.
[330] I. Waldman,et al. Candidate gene studies of ADHD: a meta-analytic review , 2009, Human Genetics.
[331] V. Arshavsky,et al. Biology and functions of the RGS9 isoforms. , 2009, Progress in molecular biology and translational science.
[332] P. Greengard,et al. Application of a Translational Profiling Approach for the Comparative Analysis of CNS Cell Types , 2008, Cell.
[333] C. Debattista,et al. Utility of Atypical Antipsychotics in the Treatment of Resistant Unipolar Depression , 2009, CNS drugs.
[334] R. Bressan,et al. Molecular Imaging Studies in Parkinson Disease: Reducing Diagnostic Uncertainty , 2009, The neurologist.
[335] P. Gorwood,et al. Genetics of dopamine receptors and drug addiction: a comprehensive review , 2009, Behavioural pharmacology.
[336] C. Antke,et al. In vivo imaging of synaptic function in the central nervous system: II. Mental and affective disorders , 2009, Behavioural Brain Research.
[337] Li-Huei Tsai,et al. Disrupted in Schizophrenia 1 Regulates Neuronal Progenitor Proliferation via Modulation of GSK3β/β-Catenin Signaling , 2009, Cell.
[338] M. Tohen,et al. Antipsychotic agents in the treatment of bipolar mania. , 2009, Bipolar disorders.
[339] D. Collier,et al. An association study of the neuregulin 1 gene, bipolar affective disorder and psychosis , 2009, Psychiatric genetics.
[340] K. Neve,et al. A Dopamine D2 Receptor Mutant Capable of G Protein-Mediated Signaling but Deficient in Arrestin Binding , 2007, Molecular Pharmacology.
[341] B. O'dowd,et al. Calcium Signaling by Dopamine D5 Receptor and D5-D2 Receptor Hetero-Oligomers Occurs by a Mechanism Distinct from That for Dopamine D1-D2 Receptor Hetero-Oligomers , 2009, Molecular Pharmacology.
[342] Masahiko Watanabe,et al. PSD-95 Uncouples Dopamine–Glutamate Interaction in the D1/PSD-95/NMDA Receptor Complex , 2009, The Journal of Neuroscience.
[343] V. A. Villar,et al. G Protein-coupled Receptor Kinase 4 (GRK4) Regulates the Phosphorylation and Function of the Dopamine D3 Receptor* , 2009, The Journal of Biological Chemistry.
[344] C. Iitaka,et al. Getting specialized: presynaptic and postsynaptic dopamine D2 receptors. , 2009, Current opinion in pharmacology.
[345] J. Traynor,et al. RGS9-2: probing an intracellular modulator of behavior as a drug target. , 2009, Trends in pharmacological sciences.
[346] David Coghill,et al. The genetics of attention-deficit/hyperactivity disorder , 2009, Expert review of neurotherapeutics.
[347] R. Gainetdinov,et al. Morphine-induced physiological and behavioral responses in mice lacking G protein-coupled receptor kinase 6. , 2009, Drug and alcohol dependence.
[348] H. Dohlman. RGS proteins the early days. , 2009, Progress in molecular biology and translational science.
[349] D. Sibley,et al. G Protein-coupled Receptor Kinase-2 Constitutively Regulates D2 Dopamine Receptor Expression and Signaling Independently of Receptor Phosphorylation* , 2009, The Journal of Biological Chemistry.
[350] K. Neve,et al. An Intracellular Loop 2 Amino Acid Residue Determines Differential Binding of Arrestin to the Dopamine D2 and D3 Receptors , 2009, Molecular Pharmacology.
[351] Paul Greengard,et al. Histone H3 Phosphorylation is Under the Opposite Tonic Control of Dopamine D2 and Adenosine A2A Receptors in Striatopallidal Neurons , 2009, Neuropsychopharmacology.
[352] M. Houslay. Arrestin Times for Developing Antipsychotics and β-Blockers , 2009, Science Signaling.
[353] Xin Duan,et al. DISC 1 Regulates New Neuron Development in the Adult Brain via Modulation of AKT-mTOR Signaling through KIAA 1212 , 2009 .
[354] R. Gainetdinov,et al. Akt/GSK3 signaling in the action of psychotropic drugs. , 2009, Annual review of pharmacology and toxicology.
[355] D. Sibley,et al. Molecular Pharmacology of the Dopamine Receptors , 2009 .
[356] A. Carlsson,et al. The 'atypicality' of antipsychotics: a concept re-examined and re-defined , 2009, Nature Reviews Drug Discovery.
[357] N. Volkow,et al. Imaging dopamine's role in drug abuse and addiction , 2009, Neuropharmacology.
[358] E. Unterwald,et al. Regulation of dynamin 2 and G protein‐coupled receptor kinase 2 in rat nucleus accumbens during acute and repeated cocaine administration , 2009, Synapse.
[359] B. O'dowd,et al. Calcium signaling cascade links dopamine D1–D2 receptor heteromer to striatal BDNF production and neuronal growth , 2009, Proceedings of the National Academy of Sciences.
[360] C. Antke,et al. In vivo imaging of synaptic function in the central nervous system I. Movement disorders and dementia , 2009, Behavioural Brain Research.
[361] G. Fisone,et al. Looking BAC at striatal signaling: cell-specific analysis in new transgenic mice , 2009, Trends in Neurosciences.
[362] T. Sotnikova,et al. Hyperdopaminergic Tone Erodes Prefrontal Long-Term Potential via a D2 Receptor-Operated Protein Phosphatase Gate , 2009, The Journal of Neuroscience.
[363] Wenjun Gao,et al. Activation of Glycogen Synthase Kinase-3β Is Required for Hyperdopamine and D2 Receptor-Mediated Inhibition of Synaptic NMDA Receptor Function in the Rat Prefrontal Cortex , 2009, The Journal of Neuroscience.
[364] H. Dohlman. Chapter 1 RGS Proteins , 2009 .
[365] Xin Duan,et al. DISC1 Regulates New Neuron Development in the Adult Brain via Modulation of AKT-mTOR Signaling through KIAA1212 , 2009, Neuron.
[366] D. Sibley,et al. D5 Dopamine Receptors are Required for Dopaminergic Activation of Phospholipase C , 2009, Molecular Pharmacology.
[367] P. Greengard,et al. l‐DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice , 2009, Journal of neurochemistry.
[368] H. Corrêa,et al. The leukocytes expressing DARPP-32 are reduced in patients with schizophrenia and bipolar disorder , 2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[369] M. Millan. From the cell to the clinic: a comparative review of the partial D₂/D₃receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease. , 2010, Pharmacology & therapeutics.
[370] Younglim Lee,et al. Glutamatergic (N-Methyl-d-aspartate Receptor) Hypofrontality in Schizophrenia: Too Little Juice or a Miswired Brain? , 2010, Molecular Pharmacology.
[371] N. Volkow,et al. Neurocircuitry of Addiction , 2010, Neuropsychopharmacology.
[372] W. Drevets,et al. A kinesin signaling complex mediates the ability of GSK-3β to affect mood-associated behaviors , 2010, Proceedings of the National Academy of Sciences.
[373] J. Lieberman,et al. Signaling pathways in schizophrenia: emerging targets and therapeutic strategies. , 2010, Trends in pharmacological sciences.
[374] A. Cincotta,et al. Bromocriptine – unique formulation of a dopamine agonist for the treatment of type 2 diabetes , 2010, Expert opinion on pharmacotherapy.
[375] Qin Li,et al. Lentiviral Overexpression of GRK6 Alleviates l-Dopa–Induced Dyskinesia in Experimental Parkinson’s Disease , 2010, Science Translational Medicine.
[376] Pieter Rondou,et al. The dopamine D4 receptor: biochemical and signalling properties , 2010, Cellular and Molecular Life Sciences.
[377] J. Sweatt,et al. Deficiency in the Inhibitory Serine-Phosphorylation of Glycogen Synthase Kinase-3 Increases Sensitivity to Mood Disturbances , 2010, Neuropsychopharmacology.
[378] P. Spano,et al. Dimerization of dopamine D1 and D3 receptors in the regulation of striatal function. , 2010, Current opinion in pharmacology.
[379] B. O'dowd,et al. Heteromerization of dopamine D2 receptors with dopamine D1 or D5 receptors generates intracellular calcium signaling by different mechanisms. , 2010, Current opinion in pharmacology.
[380] Laurence J. Miller,et al. Seven Transmembrane Receptors as Shapeshifting Proteins: The Impact of Allosteric Modulation and Functional Selectivity on New Drug Discovery , 2010, Pharmacological Reviews.
[381] M. Podda,et al. Dopamine D1-like receptor activation depolarizes medium spiny neurons of the mouse nucleus accumbens by inhibiting inwardly rectifying K+ currents through a cAMP-dependent protein kinase A-independent mechanism , 2010, Neuroscience.
[382] A. Spada,et al. Pharmacogenetics of D2 dopamine receptor gene in prolactin-secreting pituitary adenomas , 2010, Expert opinion on drug metabolism & toxicology.
[383] L. Luttrell,et al. Beyond Desensitization: Physiological Relevance of Arrestin-Dependent Signaling , 2010, Pharmacological Reviews.
[384] J. Bos,et al. Epac: defining a new mechanism for cAMP action. , 2010, Annual review of pharmacology and toxicology.
[385] W. Yao,et al. D1 and D2 dopamine receptors in separate circuits cooperate to drive associative long-term potentiation in the prefrontal cortex , 2010, Proceedings of the National Academy of Sciences.
[386] Mark J. Thomas,et al. R7BP Complexes With RGS9-2 and RGS7 in the Striatum Differentially Control Motor Learning and Locomotor Responses to Cocaine , 2010, Neuropsychopharmacology.
[387] C. Gerfen,et al. Identification of RanBP 9/10 as Interacting Partners for Protein Kinase C (PKC) γ/δ and the D1 Dopamine Receptor: Regulation of PKC-Mediated Receptor Phosphorylation , 2010, Molecular Pharmacology.
[388] C. Lüscher,et al. Emerging roles for G protein-gated inwardly rectifying potassium (GIRK) channels in health and disease , 2010, Nature Reviews Neuroscience.
[389] Dagoberto Tapia,et al. Different Corticostriatal Integration in Spiny Projection Neurons from Direct and Indirect Pathways , 2010, Front. Syst. Neurosci..
[390] Paul Greengard,et al. Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors , 2010, Proceedings of the National Academy of Sciences.
[391] B. Kolachana,et al. Epistatic and Functional Interactions of Catechol-O-Methyltransferase (COMT) and AKT1 on Neuregulin1-ErbB Signaling in Cell Models , 2010, PloS one.
[392] M. Millan,et al. Dopamine D2-D3 receptor heteromers: pharmacological properties and therapeutic significance. , 2010, Current opinion in pharmacology.
[393] S. Kéri,et al. Suppression of the P50 evoked response and neuregulin 1-induced AKT phosphorylation in first-episode schizophrenia. , 2010, The American journal of psychiatry.
[394] J. Beaulieu,et al. Confocal Analysis of Cholinergic and Dopaminergic Inputs onto Pyramidal Cells in the Prefrontal Cortex of Rodents , 2010, Front. Neuroanat..
[395] K. Fuxe,et al. Molecular integration via allosteric interactions in receptor heteromers. A working hypothesis. , 2010, Current opinion in pharmacology.
[396] S. Konitsiotis,et al. Randomized trials of dopamine agonists in restless legs syndrome: a systematic review, quality assessment, and meta-analysis. , 2010, Clinical therapeutics.
[397] E. Borrelli,et al. Regulation of BMAL1 Protein Stability and Circadian Function by GSK3β-Mediated Phosphorylation , 2010, PloS one.
[398] P. Strange,et al. Analysis of the actions of the novel dopamine receptor‐directed compounds (S)‐OSU6162 and ACR16 at the D2 dopamine receptor , 2010, British journal of pharmacology.
[399] J. Javitch,et al. Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action. , 2010, The American journal of psychiatry.
[400] Keshava Rajagopal,et al. Teaching old receptors new tricks: biasing seven-transmembrane receptors , 2010, Nature Reviews Drug Discovery.
[401] P. Frankland,et al. Uncoupling the D1-N-Methyl-D-Aspartate (NMDA) Receptor Complex Promotes NMDA-Dependent Long-Term Potentiation and Working Memory , 2010, Biological Psychiatry.
[402] Anatol C. Kreitzer,et al. Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry , 2010, Nature.
[403] T. Daigle,et al. A Dopamine D1 Receptor-Dependent β-Arrestin Signaling Complex Potentially Regulates Morphine-Induced Psychomotor Activation but not Reward in Mice , 2011, Neuropsychopharmacology.
[404] S. Kéri,et al. The relationship among neuregulin 1-stimulated phosphorylation of AKT, psychosis proneness, and habituation of arousal in nonclinical individuals. , 2011, Schizophrenia bulletin.
[405] J. Roder,et al. Genetic and pharmacological evidence for schizophrenia‐related Disc1 interaction with GSK‐3 , 2011, Synapse.
[406] T. Kuno,et al. Association of calcineurin A gamma subunit (PPP3CC) and early growth response 3 (EGR3) gene polymorphisms with susceptibility to schizophrenia in a Japanese population , 2011, Psychiatry Research.
[407] M. Cyr,et al. Molecular and cellular events of dopamine D1 receptor‐mediated tau phosphorylation in SK‐N‐MC cells , 2011, Synapse.